Viewing Study NCT00800995


Ignite Creation Date: 2025-12-24 @ 1:15 PM
Ignite Modification Date: 2025-12-28 @ 9:11 PM
Study NCT ID: NCT00800995
Status: COMPLETED
Last Update Posted: 2008-12-03
First Post: 2008-12-02
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
Sponsor: Centre de Recherche en Nutrition Humaine Rhone-Alpe
Organization:

Study Overview

Official Title: SOD as Antioxidant Treatment OF ARMD
Status: COMPLETED
Status Verified Date: 2008-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: INTRODUCTION:

Acting directly on the anti-radical enzyme chain, the superoxide dismutase (SOD), a major enzyme of the anti-oxidant system, provides an alternative of the antioxidants treatment in ARMD. Its synthesis depends on the cellular oxygenated reactive species, and leads to the conversion of the superoxide ion (O2-) into hydrogen peroxide (H2O2). This compound is the cell watch guard continuously regulating a free radicals' detoxifying chain. Subsequently, by increasing the production of H2O2, the administration of SOD can trigger endogenous/internal antioxidant mechanisms.

Oral administration of SOD is possible in its galenic form, Glisodine. The purpose of this study was to evaluate the protective effect of SOD on the bilateralization of the disease.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: